We read with interest the study by Navare et al. (1). We congratulate the authors for the original contribution by showing that the combination of function and perfusion assessment with this technique improves risk stratification. We were, however, concerned about the high event rate of 2.4% in patients with normal perfusion and function. The investigators pointed to the fact that inability to exercise is associated with adverse outcome regardless of the results of stress testing, which has been confirmed by previous studies (2). An important explanation would also be the fact that many of the patients who have a contraindication for vasodilator stress are likely to have dyspnea. The recent study by Abidov et al. (3) as shown that dyspnea is associated with worse survival among those with and without coronary artery disease referred for nuclear stress testing.
